1. |
中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Fundus Disease Group, Ophthalmology Society of Chinese Medical Association. Guidelines for clinical diagnosis and treatment of diabetic retinopathy (2014)[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
|
2. |
Tan GS, Cheung N, Simó R, et al. Diabetic macular oedema[J]. Lancet Diabetes Endocrinol, 2017, 5(2): 143-155. DOI: 10.1016/s2213-8587(16)30052-3.
|
3. |
Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
|
4. |
Wykoff CC. Thresholds for initiating treatment of eyes with diabetic macular edema and good vision: consideration of DRCR. Net Protocol V results[J]. Ophthalmol Retina, 2019, 3(11): 917-919. DOI: 10.1016/j.oret.2019.07.007.
|
5. |
Ishibashi T, Li X, Koh A, et al. The reveal study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema[J]. Ophthalmology, 2015, 122(7): 1402-1415. DOI: 10.1016/j.ophtha.2015.02.006.
|
6. |
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase Ⅱ study[J]. Diabetes Care, 2010, 33(11): 2399-2405. DOI: 10.2337/dc10-0493.
|
7. |
Wykoff CC, Nittala MG, Villanueva Boone C, et al. Final outcomes from the randomized RECOVERY trial of Aflibercept for retinal nonperfusion in proliferative diabetic retinopathy[J]. Ophthalmol Retina, 2022, 6(7): 557-566. DOI: 10.1016/j.oret.2022.02.013.
|
8. |
Qu J, Chen X, Liu Q, et al. Prophylactic intravitreal injection of Aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: a randomized controlled trial[J/OL]. Frantiers Public Health, 2022, 10: 1067670[2023-01-11]. https://pubmed.ncbi.nlm.nih.gov/36711366/. DOI: 10.3389/fpubh.2022.1067670.
|
9. |
Arevalo JF, Lasave AF, Kozak I, et al. Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy: a prospective randomized clinical trial[J]. Am J Ophthalmol, 2019, 207: 279-287. DOI: 10.1016/j.ajo.2019.05.007.
|
10. |
董晓. 雷珠单抗对PDR患者玻璃体切割术后疗效的影响[J]. 国际眼科杂志, 2019, 19(5): 809-812. DOI: 10.3980/j.issn.1672-5123.2019.5.23.Dong X. Effect of ranibizumab on the efficacy of vitrectomy in patients with PDR[J]. Int Eye Sci, 2019, 19(5): 809-812. DOI: 10.3980/j.issn.1672-5123.2019.5.23.
|
11. |
Gerendas BS, Prager S, Deak G, et al. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema[J]. Br J Ophthalmol, 2018, 102(2): 195-203. DOI: 10.1136/bjophthalmol-2017-310483.
|
12. |
Reznicek L, Cserhati S, Seidensticker F, et al. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment[J/OL]. Acta Ophthalmol, 2013, 91(7): e529-536[2013-05-07]. https://pubmed.ncbi.nlm.nih.gov/23647578/. DOI: 10.1111/aos.12153.
|
13. |
Karst SG, Lammer J, Mitsch C, et al. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(1): 49-58. DOI: 10.1007/s00417-017-3828-1.
|
14. |
Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab[J]. Ophthalmology, 2015, 122(7): 1395-1401. DOI: 10.1016/j.ophtha.2015.02.036.
|
15. |
Lammer J, Bolz M, Baumann B, et al. Detection and analysis of hard exudates by polarization-sensitive optical coherence tomography in patients with diabetic maculopathy[J]. Invest Ophthalmol Vis Sci, 2014, 55(3): 1564-1571. DOI: 10.1167/iovs.13-13539.
|
16. |
Hwang HS, Chae JB, Kim JY, et al. Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment[J]. Invest Ophthalmol Vis Sci, 2017, 58(13): 5958-5967. DOI: 10.1167/iovs.17-22725.
|
17. |
Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema[J]. JAMA Ophthalmol, 2014, 132(11): 1309-1316. DOI: 10.1001/jamaophthalmol.2014.2350.
|
18. |
Grewal DS, Hariprasad SM, Jaffe GJ. Role of disorganization of retinal inner layers as an optical coherence tomography biomarker in diabetic and uveitic macular edema[J]. Ophthalmic Surg Lasers Imaging Retina, 2017, 48(4): 282-288. DOI: 10.3928/23258160-20170329-02.
|
19. |
Santos AR, Costa MÂ, Schwartz C, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: The CHARTRES Study[J]. Retina, 2018, 38(6): 1110-1119. DOI: 10.1097/iae.0000000000001687.
|